Cue Biopharma Inc (CUE) stock is lower by -33.32% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives CUE stock a score of 34 out of a possible 100.
That rank is primarily influenced by a long-term technical score of 6. CUE's rank also includes a short-term technical score of 8. The fundamental score for CUE is 88. In addition to the average rating from Wall Street analysts, CUE stock has a mean target price of 29.25. This means analysts expect the stock to rise 124.48% over the next 12 months.
What's Happening with CUE Stock Today
Cue Biopharma Inc (CUE) stock is higher by 4.49% while the S&P 500 is higher by 1.07% as of 12:55 PM on Thursday, Apr 15. CUE is higher by $0.56 from the previous closing price of $12.47 on volume of 188,265 shares. Over the past year the S&P 500 is higher by 49.78% while CUE is lower by -33.32%. CUE lost -$1.56 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Cue Biopharma Inc (CUE) Stock.
